United Therapeutics (NASDAQ:UTHR) will be posting its quarterly earnings results before the market opens on Wednesday, October 31st. Analysts expect United Therapeutics to post earnings of $3.23 per share for the quarter.
Shares of UTHR traded up $1.20 during trading hours on Tuesday, hitting $118.87. The stock had a trading volume of 2,948 shares, compared to its average volume of 328,121. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The stock has a market cap of $5.16 billion, a P/E ratio of 10.91, a P/E/G ratio of 26.72 and a beta of 1.20.
Several equities analysts recently issued reports on the stock. Wedbush boosted their target price on shares of United Therapeutics from $234.00 to $253.00 and gave the company an “outperform” rating in a research note on Thursday, August 2nd. HC Wainwright restated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics in a research report on Thursday, August 2nd. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Thursday, August 16th. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 price objective for the company in a research report on Saturday, July 7th. Finally, BidaskClub cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, September 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. United Therapeutics has a consensus rating of “Hold” and an average target price of $138.86.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Article: What are the reasons investors use put options?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.